(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 5.43% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Illumina's revenue in 2026 is $4,288,000,000.On average, 22 Wall Street analysts forecast ILMN's revenue for 2026 to be $686,377,600,000, with the lowest ILMN revenue forecast at $648,483,200,000, and the highest ILMN revenue forecast at $727,939,200,000. On average, 20 Wall Street analysts forecast ILMN's revenue for 2027 to be $729,925,600,000, with the lowest ILMN revenue forecast at $678,432,000,000, and the highest ILMN revenue forecast at $819,619,200,000.
In 2028, ILMN is forecast to generate $765,680,800,000 in revenue, with the lowest revenue forecast at $712,506,400,000 and the highest revenue forecast at $812,743,200,000.